A pharmacovigilance team managing multiple products globally runs hundreds of literature searches each week. They log adverse event reports from call centers, emails, patient portals, and clinical trial feeds. Every day, cases arrive that require review, coding, triage, narrative writing, duplicate checking, and regulatory submission — all under strict timelines that most health authorities will not extend.
For years, the industry’s answer to this workload was more personnel, more spreadsheets, and more manual reviews. That answer no longer holds.
The efficiency case for AI-assisted literature screening in pharmacovigilance is well supported by research. A synthesis published in Frontiers in Pharmacology in January 2025, drawing on multiple structured literature review automation studies, found that AI-assisted screening tools can reduce the volume of articles requiring human review to as low as 23% of the total retrieved, with time savings per review cycle ranging from 7 to 86 hours. While this isn’t exactly a theoretical reduction, it changes what pharmacovigilance professionals are doing each week and determines whether recovered hours are allocated to high-value medical analysis or returned to the same manual queue.
This article explores where those efficiency gains actually come from, how they can create more capacity for high-value clinical assessment, and what it takes to implement AI-based literature review capabilities in a way that is technically sound, operationally reliable, and ready for regulatory scrutiny.
Why Manual PV Workflows Hit a Ceiling
Manual pharmacovigilance processes were designed for a different era. Case volumes were lower. Reporting channels were fewer. The regulatory landscape, though complex, was more contained.
Today, those assumptions no longer apply.
The EMA’s 2024 Annual Report on EudraVigilance reviewed 1,254 potential safety signals. Of those, 71 were confirmed and assessed by PRAC — approximately 5.7% of all signals initially reviewed. That ratio reflects a structural challenge that begins upstream, in the literature monitoring and case intake workflows that feed the safety database. When screening processes generate high noise volumes, safety teams spend more time triaging irrelevant content than evaluating genuine signals, and validation rates reflect that downstream.
When teams spend most of their bandwidth on volume management rather than medical evaluation, signal detection suffers. When case narratives are written manually across distributed teams with no standardized guidance, coding inconsistencies accumulate. When literature triage is done by keyword search alone, pharmacokinetic studies and off-label mentions crowd out genuine adverse event reports.
These are not hypothetical failure modes. They are the documented, recurring findings that appear in FDA Warning Letters, regulatory inspection observations, and post-market safety commitments.
50
New molecular entities cleared by the FDA in 2024. Each approval extends a post-marketing surveillance obligation that the sponsoring organization must maintain indefinitely — expanding workloads without automatic increases in team capacity.
The ceiling on manual PV workflows is a compliance ceiling, not just an efficiency one.
The AI Stack in Pharmacovigilance: An Overview
AI is not a single technology applied uniformly across pharmacovigilance. It is a set of distinct capabilities, each suited to a different part of the workflow.
| PV Workflow Stage | Clinevo Product | Technology Approach | What It Replaces |
|---|---|---|---|
| Case Intake — unstructured data extraction | Case Intake / MICC | GenAI: NLP and LLM-based extraction from PDFs, emails, call transcripts | Manual transcription and data entry by case processors |
| Case Intake — voice-to-text for telephony | Case Intake / MICC | GenAI: AI voice analytics with real-time speech-to-text | Manual note-taking during and after calls |
| Case Intake — narrative generation | Case Intake / MICC | GenAI: LLM-assisted case narrative drafting with human sign-off | Manual narrative writing by qualified reviewers |
| Literature surveillance — triage and ICSR detection | Literature Management | GenAI: NLP classification, semantic search, AI-driven relevance scoring | Manual abstract screening across hundreds of weekly search results |
| Literature surveillance — duplicate detection | Literature Management | GenAI: Narrative analysis to identify same-patient cases across publications | Manual cross-database comparison and DOI matching |
| Safety database — case routing and validation | Safety Database | Automation: Rule-based intelligent routing, anomaly detection, E2B validation | Manual case assignment, field-by-field data validation |
| Safety database — duplicate detection | Safety Database | Automation: Probabilistic matching algorithms on E2B R2/R3 XML imports | Manual duplicate searches on incoming case records |
| Signal detection | Signal Detection | Automation: ML algorithms, including PRR, ROR, EB05, EBGM, and Chi-Square analytics | Periodic manual disproportionality analysis |
| Regulatory submission | Safety Database | Automation: E2B R3 mapping and integrated gateway connectivity | Manual field entry and separate submission tools |
Not every stage in this table uses the same type of technology, and that distinction matters. Case intake and literature management are the stages where GenAI and LLMs deliver meaningful value, because both involve processing large volumes of unstructured, free-text content that rules-based systems cannot reliably interpret. Safety database operations and signal detection, by contrast, operate on structured data flows where automation and ML algorithms are the appropriate and proven approach. Conflating the two creates false expectations and, in a regulated environment, governance gaps.
AI in Pharmacovigilance Case Intake: From Unstructured Data to Case-Ready Reports
Case intake is the entry point of the pharmacovigilance system. It is also where the most data quality problems originate.
Adverse event reports rarely arrive in clean, structured formats. They come in as call center transcripts, handwritten consumer emails, scanned CIOMS forms, patient portal submissions, and affiliate safety reports in a dozen different languages. Each source has its own structure, vocabulary, and completeness level. Manual intake teams must interpret, extract, and standardize this information before it can enter the safety database.
How AI Transforms the Intake Process
Natural Language Processing for document-based intake: NLP models trained on pharmacovigilance terminology extract core case elements, including reporter information, suspect product details, adverse event descriptions, seriousness criteria, and patient demographics – from unstructured source documents. This removes manual transcription from the most time-consuming part of the intake process and reduces data entry-related errors at the point of case creation.
AI-powered voice analytics for telephony intake: For telephone-based adverse event reporting through platforms such as AWS Connect, AI converts speech to text in real time, identifies safety-relevant elements within the transcript, and pre-populates case forms. Human reviewers validate the output rather than performing the extraction themselves.
Intelligent pre-population with confidence scoring: As case fields are populated automatically, each entry is assigned a confidence score. High-confidence entries pass through to review without interruption. Low-confidence entries are flagged for human verification. This mechanism focuses the reviewer’s attention on ambiguous cases rather than distributing it equally across routine entries.
Multi-language identification and processing: Global adverse event reporting requires processing cases in multiple languages. AI systems with multi-language support identify the source language automatically and apply language-appropriate extraction models, removing the need for manual language routing.
AI-assisted case triage: Once a case is structured, AI-driven routing assigns it based on seriousness classification, product, therapeutic area, and reporting jurisdiction. Expedited cases are automatically flagged against submission deadline trackers. Non-expedited cases follow pre-configured processing pathways.
Regulatory Compliance in Automated Case Intake
For US-based organizations operating under FDA requirements, automated case intake systems must meet the same compliance standards as any validated computerized system used in regulated operations. This includes:
- Full compliance with 21 CFR Part 11 for electronic records and electronic signatures
- Tamper-evident, timestamped audit trails covering every case action from intake through submission
- Validation documentation demonstrating that the system performs within defined parameters
- Documented human oversight protocols that specify when AI-extracted data requires reviewer verification
Automation does not reduce the organization’s responsibility for case quality. It shifts where qualified human judgment is applied — from data extraction to data validation.
Automation in Case Processing: From Structured Data to Submission-Ready
What GenAI handles at the intake stage – extracting case-relevant information from unstructured sources and converting it into structured case fields – is precisely where its role ends. Once a structured case record enters the safety database, a different set of capabilities takes over: rule-based automation, intelligent workflow routing, and validated processing logic built directly into the database architecture.
Case processing in the safety database operates on data that is already structured at this point, where deterministic logic, probabilistic matching, and rules-based validation produce consistent, auditable, and reproducible outputs. These are exactly the properties regulators demand from systems that generate regulatory submissions.
What Automated Case Processing Covers
Intelligent case routing: Cases are assigned automatically based on seriousness, product, therapeutic area, and reporting jurisdiction as soon as they enter the processing queue. Serious and unexpected cases meeting expedited reporting criteria are identified and escalated without manual intervention. Non-expedited cases follow pre-configured processing pathways based on case type and product scope, eliminating the queue management burden on safety operations teams.
Automated duplicate detection: Before a case proceeds through the processing workflow, probabilistic matching algorithms compare it against existing case records using key identifiers, including patient demographics, adverse event terms, suspect product details, and report dates. Potential duplicates are flagged at the point of entry rather than during quality review or post-submission, where a duplicate ICSR reaching a health authority creates a corrective reporting obligation. The same matching logic applies to E2B R2 and R3 XML imports, covering cases transferred electronically from partner systems and affiliates.
Real-time data quality validation: Automated soft validations and E2B structural validations check incoming case data against required field specifications, controlled vocabulary standards, and message structure rules as each case is processed. Fields that fail validation are flagged before the case proceeds, not at the point of gateway submission. This internal check layer prevents the downstream rework that regulatory gateway rejections create and protects submission timelines.
Automated follow-up assessment: When a follow-up report arrives for an existing case, a difference module identifies which fields have changed and whether those changes constitute a significant or non-significant follow-up. Significant follow-ups generate a new ICSR version and reset applicable reporting timelines. Non-significant follow-ups are absorbed without triggering duplicate case creation – a common source of database inflation in organizations managing follow-up reports manually without structured comparison logic.
SLA-driven compliance tracking: Each case is tracked against its applicable reporting deadline from the point of receipt. Configurable alerts notify case owners and safety managers as cases approach their SLA thresholds, before a deadline is breached. For organizations operating across multiple regulatory jurisdictions – each with distinct expedited reporting windows – automated SLA tracking is not an operational convenience. It is a core compliance mechanism that removes reliance on manual deadline management.
Regulatory submission through integrated gateway configurations: Auto-reporting rules within the database determine which cases trigger regulatory submissions, to which authorities, and under which timelines. Submissions are transmitted directly from the database through secure, validated gateway connections, without manual file exports or format conversions. Transmission acknowledgments and submission records are logged within the same environment where the case was processed, maintaining a single coherent audit trail from intake to submission.
The Same Pipeline Receives Literature-Sourced ICSRs
The processing and submission pipeline described above handles spontaneous cases arriving from the case intake module. It also receives validated ICSRs identified through the literature monitoring platform. Both sources enter the safety database through the same automated workflow. This is what makes the integration across the two GenAI-powered products and this automation layer consequential: regardless of whether a case originates from a call center transcript, a patient portal submission, or a journal abstract, it follows the same structured, rules-governed processing path to regulatory submission.
AI-based Automation in PV Literature Monitoring: From Volume to Signal
Literature monitoring is one of the most resource-intensive activities in pharmacovigilance, and one of the most exposed to compliance risk when managed at scale without automation.
EMA’s Good Pharmacovigilance Practices Module VI requires systematic literature surveillance at a minimum weekly frequency, with full documentation of search strategies and screening decisions. The FDA applies the same expectation. For a company monitoring multiple PV products, that mandate translates into hundreds of weekly searches across indexed databases, regulatory websites, and conference repositories.
The volume problem is significant on its own. The quality problem that follows it is more consequential.
Where Manual Literature Monitoring Fails
False positive accumulation: Broad keyword searches surface pharmacokinetic studies, in vitro research, and review articles that mention a drug name without containing any reportable adverse event content. Without AI-powered triage to filter these before human review, safety teams spend substantial time screening content that should never have entered the review queue.
Duplicate case proliferation: A single patient case can appear as a conference abstract, a full journal article, and a cited case in a systematic review, all within the same calendar year. A 2024 scoping review in BMJ Open found that 11% of literature-sourced reports in the WHO pharmacovigilance database were duplicates, compared to a 2.5% duplicate rate across all other reporting channels. Each duplicate that creates a separate ICSR inflates case counts, distorts signal detection, and consumes investigative resources.
The E2B handoff gap: Even when a valid ICSR is correctly identified in the literature, transferring that data into a safety database is frequently a manual process. Demographics, adverse event terms, drug exposure information, and publication metadata are transcribed by hand into platforms such as Argus Safety or ArisGlobal. Manual transcription introduces errors. It also produces no automatic audit trail connecting the source article to the final case record.
What End-to-End AI Literature Automation Looks Like
Multi-database simultaneous search: Automated systems execute queries across PubMed, EMBASE, regional databases, regulatory websites, and clinical trial registries simultaneously, handling syntax differences between platforms automatically. Direct API integration with PubMed and EMBASE enables scheduled, scripted queries and bulk article retrieval without manual search recreation each week.
AI-powered triage and classification: NLP engines trained on pharmacovigilance terminology classify abstracts by ICSR relevance before any human review is required. A 2025 systematic review in Research in Social and Administrative Pharmacy found that externally validated ML models achieved 81.5% sensitivity and 79.5% specificity for adverse drug reaction identification, outperforming internally validated models at 78.1% sensitivity and 70.6% specificity. The system distinguishes between a pharmacokinetic study that mentions a drug name and a case report that contains a reportable adverse event – a distinction that rule-based keyword screening cannot reliably make.
Noise removal at scale: Automated noise filtering using curated keyword libraries reduces the volume of irrelevant content before it reaches human reviewers. Consistent logic is applied across all searches, removing the variability introduced when different team members apply different screening judgments.
Intelligent duplicate detection: Cross-referencing DOIs, normalizing author names and journal abbreviations, and applying narrative analysis can identify same-patient cases published in different formats. Detection algorithms significantly outperform manual review for cross-publication matching.High-confidence matches are merged automatically. Moderate-confidence matches are presented side by side for human review.
Automated E2B R3 case creation: Validated ICSRs are transferred into safety databases via direct API integration with E2B R3-compliant XML output. Field mapping, controlled vocabularies, and MedDRA coding are validated before production. No manual re-entry is required, and a complete audit trail connecting the source article to the final case record is generated automatically.
Automation-Driven Signal Detection: Finding Patterns Before They Become Crises
Signal detection sits downstream of case intake and literature monitoring. The quality of what enters the safety database directly determines what signal detection can find.
Traditional signal detection methods rely on periodic disproportionality analysis, using statistical algorithms such as the Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), EB05, and EBGM to identify drug-event associations that appear more frequently than expected against background rates. These methods are well-established. Their limitation is timing: periodic analysis means patterns that develop between review cycles may go undetected for weeks.
What Automation and Machine Learning Add to Signal Detection
Temporal pattern recognition: ML models monitor adverse event data continuously rather than periodically. They identify emerging clusters across time periods, demographic segments, and geographic regions in real time, reducing the lag between a pattern developing and a safety team becoming aware of it.
Propensity-score-adjusted algorithms: Confounding by indication is a persistent problem in signal detection. Drugs used in high-risk patient populations generate adverse event associations that reflect the underlying disease rather than the drug itself. Automated threshold mapping with propensity-score adjustment reduces this confounding, improving signal specificity and reducing false positive rates.
Graph-based signal analytics: Modeling drugs, events, patients, and risk factors as an interconnected network rather than independent variables enables the detection of associations that table-based disproportionality analysis misses. Hidden cross-product signals and multi-drug interactions become visible through relational data analysis.
Therapeutic area stratification: Performing disproportionality analysis within therapeutic area strata reduces competition bias from unrelated drug classes. A signal that would be diluted in a global background rate becomes statistically detectable when assessed against a therapeutically appropriate comparator population.
Integration across ICSR data sources: Signal detection that draws only from a single safety database has a narrower view of the safety profile than one that integrates data from FAERS, EVDAS, WHO VigiBase, and proprietary sources simultaneously. Database-to-database linking technology enables cross-source signal evaluation while maintaining data governance requirements.
GenAI vs Traditional Automation in PV: What the Distinction Actually Means
The distinction between traditional automation and generative AI matters for practical reasons, not just definitional ones. Choosing the wrong tool for a given task produces predictable failure modes.
Traditional Automation (RPA and Rules-Based Systems)
Traditional automation operates on predefined rules. It excels at structured, repetitive tasks where input formats are consistent, and outputs are deterministic. Routing a case from one queue to another, populating a field from a validated lookup table, flagging a case when a seriousness criterion is met – these are tasks where rule-based systems perform reliably and predictably.
The limitation appears with unstructured data. When a patient writes, “I felt a bit woozy after my pill,” a rule-based system searching for “dizziness” in a predefined synonym table may miss the event entirely. When an adverse event report arrives in an unexpected format, the system may fail and route the case to manual review. As case volumes increase, the number of exceptions that require human handling increases proportionally.
Generative AI and LLMs in Pharmacovigilance
Large Language Models (LLMs) can understand semantic context, interpret negation, and process medical intent within free-text narratives. A system built on an LLM can distinguish between “I was afraid of nausea, so I did not take the medication” (no adverse event) and “I took the medication and felt nauseous” (valid adverse event) – a distinction that trips up traditional keyword matching.
When enhanced with Retrieval-Augmented Generation (RAG) frameworks – which ground model responses in verified source documents rather than relying on training data alone – accuracy in natural language queries against complex PV databases has been shown to improve from 8.3% to 78.3%. RAG significantly reduces hallucination risk by anchoring outputs to specific, retrievable source content rather than model-generated inference.
The Risk That Comes with Generative AI
GenAI outputs can appear more authoritative than the underlying evidence warrants. Research testing six LLMs with 300 physician-validated clinical vignettes – each containing a single fabricated medical detail – found that models repeated or elaborated on the planted error in up to 83% of cases, with mitigation prompts reducing but not eliminating the risk. In a field where a single fabricated adverse event detail can trigger a regulatory response or mask a real safety signal, deploying LLMs without structured oversight protocols is not defensible.
The appropriate architecture treats GenAI as a drafting and extraction layer, with mandatory human validation before any output enters the safety database or is submitted to a regulatory authority.
| Feature | Traditional Automation | GenAI-Powered Automation |
|---|---|---|
| Data handling | Structured formats only | Unstructured text, voice, PDFs, literature |
| Context understanding | Keyword matching | Semantic, contextual, negation-aware |
| Adaptability | Fixed; breaks with format changes | Adapts to format and language variations |
| Case triage | First-in, first-out | Risk-based prioritization by seriousness |
| Scalability | Linear with volume | Handles volume spikes without proportional effort |
| Hallucination risk | None | Present; requires guardrails and human verification |
AI Governance in Pharmacovigilance: Validation, Audit Trails, and Inspection Readiness
The question regulators ask about AI in pharmacovigilance is no longer whether organizations use it. It is whether they can demonstrate control over it.
Evolving regulatory guidance from the FDA and EMA has made the expectations explicit: AI governance in pharmacovigilance must be explainable, traceable, and inspection-ready – held to the same GxP standards as any other validated system in the drug safety environment.
What Inspection-Ready AI Governance Requires
RACI-based accountability: Primary accountability for an AI system used in pharmacovigilance must sit with the PV process owner, not IT or data science. A federated governance structure with clearly defined roles for process ownership, data stewardship, technical liaison, risk management, and oversight review is necessary to answer the inspector’s first question: who is responsible for this decision?
Control plans as living documents: A control plan documents how an AI system is monitored, measured, and managed across its operational life. It specifies performance parameters, confidence thresholds that trigger human review, data drift detection protocols, and the criteria for escalating cases from automated to full human oversight. Inspectors reviewing an AI-assisted PV workflow will ask to see this document. Organizations that have not built it before deployment will be reconstructing it under inspection pressure.
Audit trails that go beyond traditional GxP requirements: Traditional audit trails capture who performed an action, when, and on what record. AI audit trails must additionally capture which model version processed each case, the confidence score assigned, the human action taken in response, and the entire data lineage from input to final output. This documentation must meet ALCOA++ standards: attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available.
Human-in-the-loop protocols with documented ramp-down criteria: Human oversight cannot be removed from AI-assisted PV workflows without documented evidence that the system has performed within defined parameters. Initial human review rates during validation are typically 100%. Reduction from that baseline requires a defined performance threshold, documented approval, and ongoing random sampling at a risk-appropriate rate.
Validation across the full AI lifecycle: Pre-deployment validation must include testing on representative datasets, bias assessment across demographic subgroups, and performance benchmarking against a qualified human standard. Post-deployment monitoring must track model accuracy, data distribution shifts, and false positive/negative rates continuously, with documented change control for any model update or retraining event.
Regulatory Considerations for AI in PV: FDA, EMA, and GxP Alignment
US-based pharmaceutical organizations deploying AI in pharmacovigilance operate within a specific regulatory framework. Understanding where that framework applies to AI decision-making is a prerequisite for compliant implementation.
FDA Requirements
Under 21 CFR Part 11, electronic records and electronic signatures used in regulated activities must be produced, managed, and stored in validated systems with secure, computer-generated, timestamped audit trails. This requirement applies to any AI system whose outputs are used in case processing, submission, or safety reporting. It means that audit trails for AI-assisted decisions are not supplementary documentation; they are a regulatory obligation.
The FDA’s expedited ICSR reporting requirement of 15 calendar days for serious and unexpected adverse reactions is a fixed compliance window. AI systems used in case intake or triage must be validated to operate within that window reliably. Performance thresholds in the control plan should be set at a level that, when met, provides documented assurance that submission timelines are achievable at normal case volumes and at peak volume periods.
EMA Requirements
EMA’s GVP Module VI establishes systematic literature surveillance requirements with weekly search frequency, full documentation of search strategies, and documented screening decisions. For organizations submitting to EMA, automated literature monitoring systems must generate audit-ready records of each search execution, the criteria applied, and the disposition of each retrieved article. These records are not optional for inspection compliance.
ICH E2B R3
ICH E2B(R3) defines the structure and content standards for electronic ICSR submissions to health authorities globally. FDA, EMA, Health Canada, PMDA, and MHRA all require submissions in this format. Automated E2B mapping in a validated system must handle controlled vocabularies, MedDRA coding, null flavors, and element relationships consistently and without manual field-by-field configuration for each case.
What "FDA-Aligned" AI Tools for PV Actually Means
A tool described as FDA-aligned for pharmacovigilance must demonstrate, through documentation and testing:
- Validation against defined performance criteria on representative PV datasets
- Audit trail architecture meeting 21 CFR Part 11 standards
- A change control process for model updates and retraining
- A documented context of use, specifying exactly which workflow steps are AI-assisted and which require human sign-off
- Vendor agreements that allow regulatory access to algorithm documentation and model performance data during inspections
The organization using the tool retains full responsibility for AI-generated outputs. Vendor certification does not substitute for internal validation and governance.
How Clinevo Integrates AI and Automation Across the PV Lifecycle
Clinevo’s pharmacovigilance platform, Clinevo OnePV, is built around the premise that compliance and operational efficiency cannot be in conflict with each other in a regulated environment. The platform brings GenAI-powered case intake, AI-enabled literature automation, automated signal detection, and E2B-compliant regulatory submission into a single, integrated environment.
A deliberate technology choice governs how each product is built. Case Intake and Literature Management use GenAI — specifically NLP and LLM-based capabilities — because both deal with high volumes of unstructured, free-text content where contextual understanding is what separates a reportable adverse event from irrelevant noise. The Safety Database and Signal Detection use sophisticated automation and ML algorithms, because both operate on structured data where rules-based logic, statistical models, and deterministic processing are the right tools. Neither product benefits from being relabelled — and doing so would create inaccurate governance documentation under GxP requirements.
Clinevo Safety Database
The Safety Database is the automation backbone of the OnePV platform. It uses intelligent rule-based workflows, anomaly detection algorithms for real-time data quality validation, and probabilistic matching for duplicate detection on E2B R2/R3 XML imports. Automated E2B follow-up assessment uses a difference module to distinguish significant from non-significant follow-ups, reducing manual case management decisions. Gateway configurations with auto-reporting rules enable regulatory submission directly from the database, with automated SLA tracking and compliance alerts for approaching deadlines. Every action is logged in a tamper-evident, timestamped audit trail aligned with 21 CFR Part 11 and Annex 11.
Clinevo Case Intake / MICC
Case Intake is one of two products in the OnePV platform built with GenAI capabilities. It captures adverse event reports from medical information call centers (including telephony integration with AWS Connect), email channels, web portals, and structured and unstructured forms. GenAI-powered voice analytics with real-time speech-to-text processes, telephony-based reports at intake. NLP extracts case elements (such as reporter details, suspect products, adverse event terms, and seriousness indicators) from unstructured PDF documents without manual transcription. Multi-language detection and processing handles reports across all major global markets without manual language routing.
Intelligent pre-population with confidence scoring focuses the human reviewer’s attention on ambiguous entries. Automated follow-up scheduling and contact optimization support completion rates for outstanding case information.
Clinevo Literature Automation Platform
Literature Management is the second product in the OnePV platform built with GenAI capabilities. The platform integrates directly with PubMed and EMBASE via official APIs, enabling scheduled queries, bulk retrieval, and machine-readable data normalization. A curated keyword library of 2.5 million-plus terms supports automated noise removal and categorization of retrieved articles into ICSR-relevant, PSUR/signal-relevant, and invalid categories before human review.
The GenAI-powered duplicate detection layer applies narrative analysis – not just DOI matching – to identify same-patient cases published across different journals and formats, addressing the cross-publication matching problem. NLP engines trained on PV terminology classify abstracts by ICSR relevance before any human review is required. Validated ICSRs are transferred via direct API integration with E2B R3-compliant XML output into connected safety databases, including Argus Safety, ArisGlobal, and Clinevo Safety, with no manual re-entry.
Clinevo Signal Management Platform
Signal Detection is automation and ML-based – there is no GenAI in this product. It uses statistical algorithms, including PRR, ROR, EB05, EBGM, and Chi-Square analytics, with propensity-score-adjusted threshold mapping to reduce confounding by indication. Graph-based analytics model drug-event-patient relationships as an interconnected network, enabling detection of cross-product associations that table-based disproportionality analysis misses. Therapeutic area stratification applies disease-context-aware detection, limiting inappropriate cross-area comparisons and lowering false positive rates. Integration with FAERS, EVDAS, WHO VigiBase, and proprietary safety databases enables cross-source signal evaluation. All of this runs as structured, auditable, and validated automation.
Built-In Compliance Architecture
Every component of the platform is designed to meet 21 CFR Part 11, EU GMP Annex 11, GxP, and GDPR requirements. Audit trails are computer-generated, timestamped, and tamper-evident. Inspection readiness is a design characteristic, not a documentation task performed before an audit.
The Integration Argument: Why Connecting the PV Pipeline Matters
AI capabilities applied at individual stages of the pharmacovigilance workflow deliver incremental improvements. AI capabilities connected across the full pipeline deliver qualitatively different outcomes.
Consider the most common integration gap: an NLP-powered literature platform that identifies a new suspected adverse reaction in a published case report, but operates as a separate system from the safety database. A safety officer must manually compare the literature finding against existing ICSRs, a process that takes hours or days. By the time the pattern is confirmed and escalated, the signal has been active for longer than necessary, and the reconciliation work required to demonstrate regulatory responsiveness adds cost and delay.
In a properly integrated PV platform, the literature finding is automatically cross-referenced against the case database, the signal detection module is alerted to the new data point, and the audit trail documenting the handoff is generated without additional steps. The outcome is faster signal identification and a single coherent data trail for inspection purposes.
Fragmented systems do not fail visibly. They fail during signal reconciliation exercises, aggregate reporting cycles, and regulatory inspections, when the cost of manual bridging between disconnected platforms becomes the bottleneck that was not visible during routine operations.
| Search & Retrieval Direct API integration with PubMed & EMBASE | The platform connects to PubMed and EMBASE through direct API integrations, enabling scheduled, AI-enabled literature workflows with full logging of query settings, timestamps, and response records. GVP Module V-compliant documentation is produced as a standard operational output — users no longer need to reconstruct search histories from downloaded logs or email threads. Every search is auditable from execution to result set. |
| AI Triage NLP Classification with 2.5M+ Keyword Library | The NLP classification layer is trained on pharmacovigilance-specific terminology, drawing on a curated library exceeding 2.5 million keywords. This enables the system to distinguish between articles that mention a drug and those that contain relevant adverse event information. Clinical relevance criteria — definitions that broad keyword matching cannot make reliably. Noise removal operates at the title and abstract level, filtering pharmaceutical studies, in-vitro research, and off-label content before they reach the human review queue. Reviewers can then focus their attention on articles that have already been screened for pharmacovigilance relevance, reducing time in the review and making manual review more efficient. |
| Duplicate Detection | The duplicate detection layer goes beyond DOI matching. It identifies situations where the same patient case has appeared across multiple publications, conference abstracts, and follow-up journal articles. |
| Narrative-Level Cross-Publication Matching | conference abstract, a full journal article, and a cited case in a subsequent systematic review — even when authors, journals, and DOIs all differ across publications. High-confidence matches are confirmed and consolidated by the system and logged in the audit trail. Cases where confidence is moderate are presented side by side for reviewer determination, keeping human judgment in place for ambiguous situations. |
| Classification Three-Category Literature Routing | Screened literature is categorized into three structured classifications: ICSRs-relevant, PSUR and Signal-relevant, and invalid. This supports cross-program and aggregate reporting simultaneously. Articles containing non-ICSR safety information relevant to periodic reporting are retained and routed appropriately, rather than excluded from the workflow entirely. |
| Case Transfer Automated E2B R3 XML Generation | For validated ICSRs, the platform generates E2B R3-compliant XML outputs, mapping all essential fields (demographics, adverse event terms, drug details, causality indicators, and source documentation), against the ICH E2B(R3) schema. This eliminates manual transcription from article to safety database and produces a regulatory gateway. |
| Compliance 21 CFR Part 11, Annex 11, GxP & GDPR | Compliance requirements are embedded in the system architecture, not layered on after the fact. Audit trails are generated as a standard operational output, covering the full pathway from search execution through triage decision, human validation, and case submission. The platform integrates in-built with Argus Safety, ArisGlobal, and Clinivo Safety, with browser-based access supporting global team collaboration across time zones. |
Frequently Asked Questions
AI applies Natural Language Processing to extract case-relevant information from unstructured source documents, including emails, PDFs, call center transcripts, and patient portal submissions. For telephony-based intake, AI voice analytics convert speech to text in real time and identify safety-relevant elements within the conversation. Extracted data is used to pre-populate case forms, with confidence scores indicating which fields require human verification. This shifts the reviewer's role from transcription to validation, reducing manual data entry and improving completeness at the point of case creation.
AI systems used in pharmacovigilance case intake must comply with 21 CFR Part 11 for electronic records and electronic signatures. This requires a validated system with secure, computer-generated, timestamped audit trails covering every case action from intake through submission. Validation documentation must demonstrate that the system performs within defined parameters on representative datasets. A documented human oversight protocol must specify which steps require a qualified reviewer's sign-off before outputs are used in regulatory reporting. The organization deploying the AI retains full accountability for the quality and accuracy of all case records, regardless of how much of the intake process is automated.
No. AI in pharmacovigilance case intake and literature review is a capacity and accuracy tool, not a replacement for qualified human judgment. The regulatory frameworks governing drug safety operations, including 21 CFR Part 11 and GVP Module VI, require human oversight at defined decision points in both case processing and literature assessment. What AI changes is where that oversight is applied. Reviewers who previously spent most of their time on data extraction and keyword screening can focus instead on medical evaluation, causality assessment, and signal interpretation, which is where their expertise is most consequential.
Validation follows the same principles applied to any GxP-regulated computerized system, with additional requirements specific to AI. Pre-deployment validation includes defining the intended use clearly, establishing performance acceptance criteria, testing against representative datasets that mirror production data, and conducting bias testing across demographic and geographic subgroups. A gold standard benchmark, typically a qualified human reviewer or validated reference dataset, is used to measure AI performance before go-live. Post-deployment monitoring tracks model accuracy, data distribution shifts, and error rates on an ongoing basis. Any model update or retraining event requires documented change control before it enters the production environment.
Automated literature surveillance addresses the manual workload at multiple stages. Direct API integration with PubMed and EMBASE removes the need for weekly manual search recreation. AI-powered triage and classification filters pharmacokinetic studies, in vitro research, and irrelevant mentions from the review queue before human reviewers see them. Intelligent duplicate detection identifies same-patient cases across different publication formats, preventing multiple reviewers from independently processing what is effectively a single case. Automated E2B R3 generation and direct API transfer to safety databases removes manual data entry from the final stage of the pipeline. Combined, these capabilities shift the majority of literature monitoring effort from data management to medical decision-making.
